Verbatim response from ChatGPT
Short answer
- Many people see meaningful weight loss within the first 3 months (often 5–10% of starting weight) and average losses of roughly 10–15% after about 1 year on semaglutide (Wegovy/Ozempic). Tirzepatide (Zepbound for weight loss; Mounjaro is the tirzepatide brand for diabetes and is used off‑label) tends to produce larger average losses in trials — commonly in the ~15–25% range at about 1 year, depending on dose.
- Sustainability: most trial data and clinical experience show that the majority of people regain at least some weight if the medication is stopped. Long‑term weight maintenance usually requires continuing treatment plus sustained lifestyle, behavioral and medical support.
More detail and what to expect
- Typical timeline
- First 1–3 months: appetite suppression and GI side effects are common; many people lose a noticeable amount (commonly several percent of body weight).
- 3–6 months: weight loss often accelerates; a lot of the drug’s benefit is seen in this window.
- 6–12+ months: weight loss often continues but usually slows and may plateau. Clinical trials report average losses at ~68–72 weeks (about 1.5 years): roughly 10–15% for semaglutide 2.4 mg (Wegovy) and larger averages (often 15–25%) for tirzepatide at higher doses.
- Why results vary
- Starting weight and body composition, dose, how quickly the med is escalated, diet and activity, adherence, underlying medical conditions, sleep, stress, and genetics all affect outcomes.
- “Average” results from trials hide a wide range — some people lose much more, some less.
- Sustainability
- Trials that stopped the drug (or people who stop in real life) generally show substantial regain over months to years. The medications change appetite and metabolic signalling; when they’re removed those signals often shift back toward higher appetite/metabolic adaptation.
- Best long‑term outcomes come from combining medication with structured behavior change: ongoing nutrition support, physical activity, sleep and stress optimization, and often continued medical therapy.
- Safety and practical points
- Common side effects: nausea, vomiting, diarrhea, constipation—usually worse during dose escalation and often improve. Less common but important risks include pancreatitis, gallbladder issues, and (in people with certain risk factors) rare concerns about medullary thyroid carcinoma — discuss with your clinician.
- Not safe in pregnancy; avoid if planning pregnancy.
- Cost and insurance coverage are variable; Wegovy and Zepbound can be expensive and may not be covered for everyone.
- Medical supervision is important for dosing, side‑effect management, and monitoring.
Specific brands/services (brief)
- Wegovy (semaglutide 2.4 mg) — FDA‑approved for chronic weight management; well studied for long‑term weight loss with structured lifestyle support.
- Zepbound (tirzepatide) — FDA‑approved for chronic weight management; trials show larger average weight loss than semaglutide in many dose comparisons.
- Mounjaro (tirzepatide) — approved for type 2 diabetes but widely used off‑label for weight loss; effective but check with your prescriber about indication and monitoring.
- Ozempic (semaglutide for diabetes) — produces weight loss too; sometimes used off‑label for weight loss but dosage/formulation differs from Wegovy.
What I can help with next
- If you tell me your current weight and realistic target, I can produce an approximate weight‑loss projection (range) for semaglutide vs tirzepatide and outline a practical plan for maximizing sustainability (diet, activity, behavioral strategies, monitoring). I can also help with questions to ask a prescriber or how to find a weight‑management clinic.